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Deregulation of the cell cycle control machinery is a frequent
event in cancer (Sherr, 1996). The majority of oncogenes and
tumour suppressor genes function in signal transduction to mimic
the effects of persistent mitogenic stimulation. Overcoming the
regulatory influences of extracellular signals facilitates continuous
cell cycling (Pardee, 1989). Yet, solid tumours exhibit consider-
able heterogeneity in cellular proliferation characteristics that
represent the final manifestation of these changes (Dolbeare,
1995).
Although certain generalizations can be made concerning the
overexpression or loss of function of a particular gene in terms of
its likely influence on cellular proliferation, the relationship is not
always obvious. Finding reliable and informative markers of
cellular proliferation is still of great importance for clinical studies
as both prognostic and predictive markers of outcome in various
tumour types.
In recent years, the identification and characterization of a
number of cell cycle-associated proteins, particularly cyclins,
cyclin-dependent kinases and their positive and negative regula-
tors (Pines, 1995), has opened up new possibilities for prolifera-
tion markers. Of these, the cyclins would appear to hold most
promise to become a surrogate marker for proliferation due to their
association with specific cell cycle checkpoints and phases (Bodey
et al, 1994; Dutta et al, 1995). The caveat to this putative role is
whether cyclins are acting as proto-oncogenes resulting in inap-
propriate expression in tumours. This is clearly the case for cyclin
D1 (Hall and Peters, 1996) and a similar role has been suggested in
some studies for cyclin A (Furihata et al, 1996; Wang et al, 1990).
However, to establish true overexpression there needs to be
comparison made with known markers of proliferation and prefer-
ably with multiple markers associated with different cell cycle
phases (Dutta et al, 1995; Handa et al, 1999). In this study we took
advantage of a cohort of patients with HNSCC who had been
administered IdUrd to measure potential doubling time (Tpot) in a
study of radical and postoperative radiotherapy. Using immuno-
histochemistry, we were able to stain IdUrd positivity to delineate
the S-phase and utilized Ki-67 expression to measure the approxi-
mate growth fraction. This enabled the evaluation of cyclin A as
marker associated with S+ G2 phase and the capability of
resolving whether inappropriate expression was present.
MATERIALS AND METHODS
Patients
The patients were drawn from a prospective study of locally
advanced squamous cell carcinoma of the head and neck treated
with surgery and postoperative radiotherapy or with radical radio-
therapy only. These patients (47 males, 18 females, ages 22–68)
were treated in the National Cancer Institute, Cairo University
during the period between 1990 and 1997 for the postoperative
group and between 1994 and 1997 for the radical group. All
patients were previously untreated, age less than 65 years, perfor-
mance status 0, 1 or 2 according to the WHO scale and had no
evidence of distant metastasis or second primary malignancy. All
specimens were taken from the primary tumour (31 oropharynx,
13 hypopharynx and 21 larynx) either at biopsy (33 patients
treated by radical radiotherapy) or resection (32 patients treated by
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tumours were classified as well differentiated, 42 were moderately
differentiated and 11 were poorly differentiated. There were 15 T2
tumours, 29 T3 and 21 T4. Thirty-seven tumours were without
nodal involvement, while 18, 8 and 2 were N1, N2 and N3 respec-
tively.
Iododeoxyuridine
5-iodo-2¢-deoxyuridine was obtained as a freeze-dried powder in
250 mg vials (NCI Investigational Drugs Brach, Bethesda, USA).
Immediately prior to injection, the drug was dissolved in 10 ml of
0.9% NaCl and then passed through a bacterial filter into a steril-
ized vial. The drug was injected 4–6 h before biopsy as an intra-
venous bolus in patients who were randomized for radical
radiotherapy, or 4–6 h before surgery in patients who were
randomized for surgery and postoperative radiotherapy.
Specimens were examined by a pathologist and pieces were either
fixed in 10% buffered formalin for immunohistochemistry or 
70% ethanol for flow cytometry.
Immunohistochemistry
Each of the three proliferation markers was stained using the same
method, with the exception that the antibody against Ki-67 was not
monoclonal and derived from rabbit. Briefly, 4 mm sections were
taken to 70% alcohol and endogenous peroxidase blocked for 30
min in methanol containing 1% H2O2. The sections were pre-
treated by 4 ´ 4 min microwave irradiation in 10 mM citrate acid.
After blocking with 1:5 normal swine serum (for Ki-67 only), the
sections were incubated with either 1:200 dilution of rabbit anti-
Ki-67 antibody (Dako Ltd, High Wycombe, UK) or 1:75 dilution
of mouse anti-BrdUrd/IdUrd antibody (Dako Ltd) or a 1:50 dilu-
tion of mouse anti-cyclin A antibody (Novocastro, Newcastle,
UK) in TBS. Incubations were either 2 h at room temperature or
overnight at 4°C. Staining was visualized using swine anti-mouse
or rabbit secondary antibody (Dako Ltd) diluted 1:350 in TBS and
incubated at room temperature for 1 h. ABComplex (Dako Ltd)
was then added for 1 h at room temperature and then DAB solution
for 10 min. The sections were counterstained with haematoxylin,
dehydrated mounted in DPX.
Assessment of labelling
The labelling of each marker was assessed in serial sections from
each tumour. Exact fields were not matched between each lable
due to the difficulty of identifying landmark features. However,
the same procedure of selecting alternating transverse and longitu-
dinal fields was used. There was no attempt to select fields of
maximum labelling. The method of quantitation involved
capturing images of between 9 and 20 high-power fields (´ 40
objective  ´ 10 eyepiece) fields using a Zeiss Axioskop trans-
illumination microscope, coupled to a JVC KY55F 3-CCD 
colour camera.
Images were grabbed by digitizing them using a Matrox Meteor
frame grabber, installed in a PCI bus machine. The images were
analysed using a manual routine within the Visilog (Noesis SA)
software package program. Labelling was assessed by marking
each positive and each negative tumour nuclei in each high-power
field, to obtain a minimum of 1000 cells per specimen. The LI was
calculated as the total number of IdUrd, Ki-67 or cyclin A-labelled
cells vs the total tumour cells counted. A correction was made for
the IdUrd LI as the total count does not take into account cell divi-
sion between injection and biopsy. A correction was made by
consideration of the flow cytometry data, in which the fraction of
the IdUrd labelled cells that had divided or remained undivided
was known. A simple proportion from uncorrected and corrected
FCM LI was used to correct the immunohistochemistry LI.
Flow cytometry
The duration of S-phase (Ts) was calculated for each specimen
using the method of Begg et al (1985) which permits the estima-
tion of Ts from a single biopsy taken several hours after the injec-
tion of IdUrd; the details of this method have been described
elsewhere (Wilson, 1998).
Statistical analysis
A variety of statistical analyses were carried out using the JMP
package (SAS Institute, Cary, NC, USA), these included
Spearman’s rank correlation, Mahalanobis outliner analysis and
Wilcoxon and Kruskal Wallis analysis of significance.
RESULTS
Immunohistochemical data
From the 65 specimens a total of 888, 931 and 710 fields were
captured and counted for IdUrd, Ki-67 and cyclin A respectively.
Within these fields, the overall median values, ranges and CVs for
the three markers are shown in Table 1, as are the same data calcu-
lated on an interpatient median value basis. It can be seen that the
median values follow the presupposed cell cycle pattern with
IdUrd giving the lowest positivity followed by cyclin A and finally
Ki-67. Each of the markers was significantly different to each
other (P > 0.0001).
Correlation analysis
Spearman’s rank analysis was carried out to correlate the three
markers. Table 2 shows that there were highly significant correlations
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Table 1 Comparison of the proliferation markers. The data are presented as the median, range and CV for
each marker as a percentage. All fields refers to complete data set whilst intertumour values were calculated
from the median values for each of the 65 specimens
Idurd Ki-67 Cyclin A
All fields 11.5 0–68.6 61.7 31.3 2.8–82.6 44.6 19.0 1.0–79.3 52.7
Intertumour median values 10.2 3.2–26.7 41.9 30.8 8.8–56.8 37.3 17.1 4.7–38.7 45.6between the three markers. Comparisons involving IdUrd had the
best correlation probabilities, while that between cyclin A and Ki-
67 was the weakest. Correlation analysis was also carried out on
the CV of the median values derived for each parameter from each
patient. The reverse relationship became apparent. The inherent
variability within specimens showed the best correlation between
cyclin A and Ki-67 (Rho 0.409, P = 0.0007), followed by cyclin A
and IdUrd (Rho 0.300, P = 0.0152) and finally the correlation
between Ki-67 and IdUrd variability failed to reach significance
(Rho 0.185, P = 0.141). There was no correlation between any of
the parameters and the Ts values.
Relationships between the markers and outlier analysis
To assess whether there was overexpression of cyclin A in some
tumours, outlier analysis was used. The Mahalanobis outlier
distance plot is useful when data are correlated, as it is possible for
a point to be unremarkable when seen along one or two axes, but
still be an outlier by violating the correlation. The analysis plots the
Mahalanobis distance of each point from the multivariate mean
(centroid). Interestingly, this analysis only revealed two outliers,
one in which the IdUrd, cyclin A and Ki-67 values were 10.1, 32.6
and 8.8% respectively, and the other which had values of 26.7,
20.0, and 51.4%. However, visual examination of the data revealed
several specimens that did not follow the expected pattern (Figure
1). The plot shows the various relationships and outliers that 
appear within the data set by plotting the difference between Ki-67
and cyclin A as a ratio of the differences between the three parame-
ters (Ki-67-cyclin A/cyclin A-IdUrd). Seven tumours showed
cyclin A values exceeding the Ki-67 value (cohort A in Figure 1).
Figure 2 shows the individual values for each parameter in this
group of tumours. In these patients the Ki-67-cyclin A/cyclin A-
IdUrd ratio is negative but approaches 0 because either the Ki-67
and IdUrd values were very close in two patients (1 and 4) or that
the Ki-67 and cyclin A values were similar in five of the patients.
In the latter group, the relationship between IdUrd and Ki-67
followed the expected pattern with at least a two-fold difference.
In these patients, the increased cyclin A value may be attributable
to overexpression and inappropriate positivity. Figure 1 also
reveals other subgroups of tumours. Cohort B represents 15
tumours in which the cyclin A values were less than the IdUrd LI,
thus producing a negative Ki-67-cyclin A/cyclin A-IdUrd ratio.
The differences were not great (up to 6.7%, Figure 2) and these
differences could be explained by counting errors or by a more
restricted cell cycle expression of cyclin A. Cohort C comprises
three tumours in which the cyclin A values only just exceeded the
IdUrd value, thus the high positive ratio. Cohort D represents a
group of nine tumours in which the cyclin A values were only
1–10% less than the Ki-67 values, while the IdUrd and Ki-67 rela-
tionship was as expected (Figure 2). These may also represent
tumours in which aberrant expression of cyclin A was present, if
the expected relationship between S+G2 and growth fraction is
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Table 2 Spearman’s rank correlation analysis for the median values for
each of the 65 patients
Variable By variable Spearman Rho Probability
Ki-67 IdUrd 0.433 0.0003
Cyclin A Idurd 0.420 0.0005
Ki-67 Cyclin A 0.356 0.0036
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Figure 1 The relationship between Ki-67, IdUrd and cyclin A expression in
65 HNSCC. The data are presented as a ratio of the difference between 
Ki-67 and cyclin A and cyclin A and IdUrd vs the difference between Ki-67
and cyclin A. This plot highlights subgroups who either overexpress or
underexpress cyclin A (A and B respectively) or tumours in which cyclin A
overexpression may be present (D) or three tumours in which cyclin A and
IdUrd values were almost identical (C). The symbols are varied for clarity.
Figure 2 Individual values for IdUrd (n n), Ki-67 ( ) and cyclin A (n) in
cohorts A, B and D defined in Figure 1.Aberrant cyclin A expression 33
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taken into account. The other cases followed the expected pattern
of cyclin A greater than the IdUrd score and thus the ratio tended
towards positive values.
Relationship with clinicopathological parameters
There was no correlation between any of the proliferation markers
and tumour site, T-stage, N-stage or differentiation.
DISCUSSION
Proliferation is a characteristic of all tumours; it is very rare to find
a specimen in which proliferating cells cannot be detected. Yet
studies in the literature report cyclin A-negative tumours (Furihata
et al, 1996) and, conversely, of cyclin A overexpressing tumours.
The former would seem unlikely considering the role of cyclin A
in controlling the onset of DNA synthesis and its requirement for
the G2-M transition. The latter is contentious unless comparisons
with known proliferation markers are conducted. It is important to
distinguish between increased expression associated with rapid
proliferation, and increased expression resulting from gene ampli-
fication or post-translational modification, if cyclin A is to be used
a proliferation marker or as another prognostic protein.
The clearest evidence of overexpression of cyclin A (and E)
resulting from gene amplification or post-translational modifica-
tion was reported in breast cancer patients by comparison with 
Ki-67 staining and S-phase fraction measured by flow cytometry
(Dutta et al, 1995). In this study, there appeared to be a small
cohort of five of 48 breast tumours which showed elevated cyclin
A, which this increased to eight when cyclin E was also consid-
ered. Recently, Handa and colleagues (Handa et al, 1999) used
both Ki-67 and in situ hybridization detection of histone H3
mRNA to compare with cyclin A expression in colorectal cancer.
Neither of these two studies was ideal. In the former, S-phase frac-
tion suffers from problems of dilution with diploid cells and in the
latter, the data were scored semi-quantitatively.
The findings in this present study of head and neck cancer are in
accord with the data in breast cancer (Dutta et al, 1995). We were
able to demonstrate seven patients (11%) in which cyclin A
exceeded the Ki-67 score. It should also be noted that there were a
further nine patients in which cyclin A values were within 10% of
the Ki-67 index. Considering the likely relationship between
‘growth fraction’ and S+G2, it cannot be discounted that these are
also examples of aberrant expression. Therefore, up to 25% of
HNSCC tumours may have evidence of overexpressed cyclin A
with regard to their proliferative state. There was no indication of
increased overall proliferation in these patients with respect to
IdUrd and Ki-67; the median values were similar to the overall
distribution. However, we also demonstrated tumours in which the
cyclin A expression may have been less than expected with refer-
ence to IdUrd staining. These may be examples of a more
restricted cell cycle distribution of cyclin A or of irregularity in
cyclin synthesis. In addition, there was a trend for the Ts values of
these tumours to be shorter (median 9.9 h vs 11.2 h overall).
The question that cannot be answered from this and other
studies is whether cyclin A expression drives the proliferation
characteristics of the tumour or is merely a consequence of prolif-
eration. This is an important issue if reports continue to imply
there is overexpression of cyclin A, whereas all that is being
demonstrated is the expected increase associated with increased
cell proliferation. In this present study, clear overexpression was
not associated with increased proliferation. Alternatively, the
influence of overexpression may be manifested in prognosis, as
has been found in a number of other studies (Aaltomaa et al, 1999;
Furihata et al, 1996; 1997 Handa et al, 1999; Kallakury et al,
1999). We have deliberately not reported the clinical outcome in
this series, as patients were treated by both postoperative and
radical therapy and by conventional, hyperfractionated and accel-
erated treatments. There is likely to be an influence of proliferation
between these schedules but the numbers are too small in each
group to be definitive. However, the overall local control and
survival rates 60% and 65% respectively; all seven patients with
aberrant overexpression of cyclin A achieved local control and are
still alive.
In summary, these data provide evidence for a small cohort of
patients with aberrant expression of cyclin A in HNSCC, the
consequence of which was not reflected in increased proliferation,
poorer prognosis or impaired survival. The role of cyclin A as an
alternative marker of proliferation would be compromised in
HNSCC without simultaneous knowledge of another proliferation
marker such as Ki-67. However, the data emphasize the hetero-
geneity of cell cycle parameters and proliferation within HNSCC.
There was not a clear-cut relationship between cyclin A expres-
sion and Ki-67 or IdUrd and this is likely to be reflected in both the
biological behaviour of the tumours and their response to therapy.
Whether the variability and unscheduled overexpression of cyclin
A confers greater prognostic potential remains to be seen; we are
currently assessing this marker in a study of 500 patients treated
by conventional or accelerated fractionation.
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